Werewolf Therapeutics (NASDAQ:HOWL) Given Buy Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Werewolf Therapeutics (NASDAQ:HOWL) in a research note published on Tuesday morning,Benzinga reports. The brokerage currently has a $15.00 target price on the stock.

Werewolf Therapeutics Stock Up 8.5 %

NASDAQ HOWL opened at $1.78 on Tuesday. The company has a current ratio of 10.10, a quick ratio of 10.10 and a debt-to-equity ratio of 0.29. Werewolf Therapeutics has a 12 month low of $1.58 and a 12 month high of $8.19. The stock’s 50 day moving average is $2.23 and its 200 day moving average is $2.76. The stock has a market cap of $79.32 million, a PE ratio of -1.16 and a beta of 0.41.

Institutional Trading of Werewolf Therapeutics

Hedge funds have recently bought and sold shares of the stock. Barclays PLC grew its position in shares of Werewolf Therapeutics by 130.1% during the third quarter. Barclays PLC now owns 54,810 shares of the company’s stock valued at $116,000 after purchasing an additional 30,990 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Werewolf Therapeutics by 6.3% during the 3rd quarter. Geode Capital Management LLC now owns 685,989 shares of the company’s stock worth $1,454,000 after acquiring an additional 40,692 shares in the last quarter. XTX Topco Ltd purchased a new stake in Werewolf Therapeutics during the third quarter valued at $45,000. State Street Corp lifted its position in Werewolf Therapeutics by 12.4% during the third quarter. State Street Corp now owns 476,439 shares of the company’s stock valued at $1,010,000 after purchasing an additional 52,528 shares during the last quarter. Finally, PFM Health Sciences LP grew its stake in shares of Werewolf Therapeutics by 4.9% in the 3rd quarter. PFM Health Sciences LP now owns 3,398,747 shares of the company’s stock worth $7,205,000 after buying an additional 157,673 shares in the last quarter. Hedge funds and other institutional investors own 64.84% of the company’s stock.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.